Can depression be treated like cancer? This startup that just raised $40M thinks so
Uncovering ways that cancer exploits cellular weakness, researchers have discovered new treatments that attack those specific pathways. Now a Bay Area biotech startup wants to take that mindset to depression and other mental disorders.
BlackThorn Therapeutics emerges from stealth mode Thursday with a $40 million Series A round that it hopes to use to advance two experimental drugs in clinical trials. The round was led by Arch Venture Partners with support from Johnson Johnson's venture capital...